Personnel loans now possible between Karolinska Institutet and the Public Health Agency of Sweden

Hansa Biopharma has announced a reorganization of its European and International Commercial and Medical Affairs operations, effective December 11, 2025.

With SEK 390 million in fresh funding and a Phase II trial in endometriosis underway, Gesynta Pharma’s CFO Michaela Gertz is navigating the financial complexities of a VC-backed biotech with precision and purpose.

As a consequence of a zero-based review of the organization, Elekta will reduce its global workforce by approximately 450 employees with a major effect on managerial positions.

On November 13, the day before the company's Extraordinary General Meeting, it was announced that Mikael Dolsten will not seek election to the Board of Directors as otherwise announced in the notice convening the meeting.

Imagine your job involves meeting with entrepreneurs and researchers who are passionate about developing drugs that could transform or save lives, and realizing you could be part of that future. That is just another “day at the office” for Ester Sklarsky, who has been a principal for the Swedish venture capital firm Sound Bioventures for the past three and a half years.

As part of this process, the company has initiated the statutory consultation required under Swedish employment law regarding a proposed reduction of six positions, which accounts for about 20 percent of its current workforce in Sweden.

Sweden's State Epidemiologist, Magnus Gisslén, resigned in August, stating that his former employer has serious problems, including lack of medical expertise in management. He has also compared the agency to its Danish equivalent, Statens Serum Institute (SSI), where "the management consists of leading medical experts and important research is conducted". NLS asked the Executive Vice President (EVP) of SSI, Tyra Grove Krause, about their management and the importance of working closely with academic partners.